Johnson & Johnson announced the launch of Phase 3 trials for its coronavirus vaccine candidate, becoming the fourth company to enter late-stage trials in the US. J&J’s vaccine is notably expected to require only one dose, compared to other vaccines currently in development (by companies including Moderna and Pfizer) that could require two doses.
Extra: Here’s a tracker of vaccines and treatments currently in development.
